Stock Market Reviews

SOPH (SOPHiA GENETICS SA) News

Get the latest news, insights, and market updates on SOPH (SOPHiA GENETICS SA). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 3 Promising Penny Stocks With Under $2B Market Cap
  As the year draws to a close, major U.S. stock indexes have seen slight declines for three consecutive sessions, reflecting ongoing market volatility and investor caution. In such times, identifying promising investment opportunities can be challenging yet rewarding. Penny stocks, despite their historical connotations, continue to offer potential value by highlighting smaller or emerging companies that may not yet be on the radar of larger investors. By focusing on those with strong...
  Dec 31, 2025 - $SOPH
• SunCar Technology Group And 2 Other Penny Stocks To Consider
  As the U.S. stock market gears up for a Thanksgiving break, major indexes are on track for their best week since June, reflecting a positive sentiment among investors. In this context, penny stocks—often representing smaller or newer companies—continue to capture interest due to their affordability and potential for growth. While the term may seem outdated, these stocks can still offer compelling opportunities when backed by strong financials and strategic positioning in the market.
  Nov 28, 2025 - $SOPH
• Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How
  TEM's surging Insights revenues, new contracts and expanded AI capabilities highlight its shift toward scalable data-driven growth.
  Nov 25, 2025 - $SOPH
• SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
  SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine.
  Nov 11, 2025 - $SOPH
• Complete Genomics and SOPHiA GENETICS Announce Integration of MSK-IMPACT® and MSK-ACCESS® Assays on DNBSEQ-T1+ Platform at AMP 2025
  Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made f
  Nov 11, 2025 - $SOPH
• SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine
  Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally. The announcement was made f
  Nov 11, 2025 - $SOPH
• Sophia Genetics SA (SOPH) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ...
  Sophia Genetics SA (SOPH) reports a 23% revenue increase and raises 2025 guidance, despite facing foreign exchange impacts and increased legal expenses.
  Nov 9, 2025 - $SOPH
• SOPHiA GENETICS (SOPH): Revenue Growth Outlook Reinforces Bull Case Despite Persistent Losses and Premium Valuation
  SOPHiA GENETICS (NasdaqGS:SOPH) remains unprofitable, with losses widening at an annual rate of 4% over the past five years. The company’s revenue is projected to climb 17.91% per year, outpacing the broader US market’s 10.5% growth rate. Despite robust revenue forecasts, investors are weighing the strong sales outlook against ongoing unprofitability and a premium Price-To-Sales Ratio compared to peers and the industry. See our full analysis for SOPHiA GENETICS. Next up, we'll see how these...
  Nov 5, 2025 - $SOPH
• SOPHiA GENETICS Reports Third Quarter 2025 Results and Increases 2025 Revenue Guidance
  SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025.
  Nov 4, 2025 - $SOPH
• Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
  Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10
  Nov 3, 2025 - $SOPH